Menu Search
Equities

Halychfarm AT

GFARM:UAX

Halychfarm AT

Actions
  • Price (UAH)100.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 60 minutes, as of Jan 10 2022.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Halychfarm AT (Halychfarm OJSC) is a Ukraine-based pharmaceutical company engaged in the production of both traditional medical products and phyto-preparations. The Company specializes in the production of herbal based medications, such as ointments, syrups, solutions, liquids, among others, and herbal extracts required for production phyto-medications. The Company is also involved in the manufacture of products in ampoules. Halychfarm is a part of the Arterium Corporation, engaged in the Ukrainian pharmaceutical industry.

  • Revenue in UAH (TTM)--
  • Net income in UAH--
  • Incorporated1993
  • Employees800.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.